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Summary
Exposure to second hand smoke (SHS) is believed to cause lung cancer. Pathological angiogenesis is a requisite for tumor
growth. Lewis lung cancer cells were injected subcutaneously into mice, which were then exposed to sidestream smoke
(SHS) or clean room air and administered vehicle, cerivastatin, or mecamylamine. SHS significantly increased tumor size,
weight, capillary density, VEGF and MCP-1 levels, and circulating endothelial progenitor cells (EPC). Cerivastatin (an
inhibitor of HMG-coA reductase) or mecamylamine (an inhibitor of nicotinic acetylcholine receptors) suppressed the effect
of SHS to increase tumor size and capillary density. Cerivastatin reduced MCP-1 levels, whereas mecamylamine reduced
VEGF levels and EPC. These studies reveal that SHS promotes tumor angiogenesis and growth. These effects of SHS are
associated with increases in plasma VEGF and MCP-1 levels, and EPC, mediated in part by isoprenylation and nicotinic
acetylcholine receptors.
Introduction and reduces apoptosis of endothelial cells; increases endothe-
lial tube formation in vitro; and augments pathological angiogen-
esis in murine models of inflammation, cancer, and atheroscle-Passive exposure to second hand smoke (SHS) is associated
with atherosclerosis and cancer (US Environmental Protection rosis (Heeschen et al., 2001, 2002, 2003).
Another modulator of angiogenesis is the class of isopren-Agency, 1992; Glantz and Parmley, 1992). Each of these to-
bacco-induced diseases requires neovascularization for growth oids, which are essential for membrane attachment and biologi-
cal activity of GTPases Ras and RhoA. In addition to reducingof the lesion. Tumor angiogenesis is a multifactorial process that
is generally required for tumor growth (Hanahan and Folkman, cholesterol levels, the inhibitors of 3-hydroxy-3methyl-glutaryl-
coenzyme A reductase (HMG-coA reductase inhibitors or stat-1996). As the tumor expands, central ischemia induces expres-
sion of angiogenic growth factors, e.g., vascular endothelial ins) inhibit synthesis of the isoprenoids geranyl and farnesyl
pyrophosphate. By doing so, statins may interrupt angiogenicgrowth factor (VEGF) or fibroblast growth factor (FGF). These
factors stimulate endothelial cells in the existing vasculature to signaling (Vincent et al., 2001). Statins interfere with post-recep-
tor signaling of VEGFR by reducing geranylation of rho kinaseproliferate and migrate through the tissue to form new endotheli-
alized channels. Circulating endothelial progenitor cells (EPCs) (Vincent et al., 2001; Weis et al., 2002; Gingras et al., 2000).
Statins inhibit the secretion of monocyte chemoattractant pro-may also contribute to tumor vascularity (Rafii, 2000). Genetic
inhibition of EPC recruitment inhibits tumor neovascularization tein-1 (MCP-1) by inhibiting farnesylation of Ras protein (Vincent
et al., 2001; Romano et al., 2000). This action of statins may(Lyden et al., 2001).
In addition to the FGF and VEGF systems, we have recently interfere with angiogenesis, as monocytes (or monocyte-like
cells that may transform into EPCs) mediate proangiogenic effectsimplicated another pathway in pathological angiogenesis (Cooke
and Bitterman, 2003). Nicotinic acetylcholine receptors (nAChRs) and have been shown to release angiogenic factors (Rehman et
al., 2003).are expressed in neuronal, endothelial, and vascular smooth mus-
cle cells. Stimulation of endothelial nAChRs induces proliferation Because nicotine is a major component of SHS, we hypothe-
S I G N I F I C A N C E
We find that second hand smoke stimulates tumor growth, in part by accelerating tumor angiogenesis, in a murine model of Lewis
lung cancer. The effects of second hand smoke are associated with increases in plasma levels of angiogenic cytokines and
circulating endothelial progenitor cells. The angiogenic effects of second hand smoke can be blocked by inhibition of the nicotinergic
acetylcholine receptor (nAChR). We have previously shown that an endothelial nAChR mediates endothelial cell proliferation and
migration, as well as modulating angiogenesis in vivo. HMG-coA reductase inhibition also suppresses tumor angiogenesis and growth
in this model. These pathophysiological insights may lead to new therapeutic avenues to reduce tumor growth and angiogenesis.
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sized that SHS would accelerate tumor angiogenesis. We hy-
pothesized that this effect may be mediated by an increase in
humoral (i.e., VEGF, MCP-1) or cellular (i.e., EPC) components
of tumor angiogenesis. We further hypothesized that these ef-
fects of SHS would be blocked by antagonists of the nAChR
or by inhibition of isoprenoid synthesis. The following study was
undertaken to test these hypotheses.
Results
Effect of second hand smoke on tumor growth
Five groups of eight or nine mice each were exposed to clean
room air or second hand smoke (SHS) for 17 days after subcuta-
neous implantation of Lewis lung cancer cells. In addition, some
animals were administered mecamylamine (an inhibitor of nico-
tinic cholinergic receptors) or cerivastatin (an HMG-coA reduc-
tase inhibitor) by osmotic minipumps.
SHS increased tumor size (1.31  0.43 cm3 versus 0.25 
0.05 cm3, SHS versus control; p  .0005) and weight (0.93 
0.27 g versus 0.17  0.08 g; SHS versus control; p  .0005)
(Figure 1). In the absence of SHS, statins had no effect on
tumor size (p  .468) or weight (p  .399). Cerivastatin and
mecamylamine both substantially blocked the effects of SHS,
each blocking about two thirds of the increase in tumor size
and weight (Figure 1).
Effects of SHS on tumor angiogenesis
Tumor vascularity was determined from cryosections of tumor
tissue derived from mice that had received a systemic infusion
of space-filling fluorescent microspheres via the left ventricle.
These studies revealed that capillary density was increased
about 2-fold in mice exposed to SHS (p  .0005) (Figure 2A).
Cerivastatin had no effect on tumor angiogenesis in mice breath-
Figure 1. Second hand smoke (SHS) accelerates tumor growthing clean room air, but blocked about two-thirds of the increment
SHS substantially increased tumor size and weight in mice (p  .0005). Ceri-in angiogenesis associated with SHS (p  .018). Mec-
vastatin blocked about two-thirds of the effect of SHS (p  .0005 for SHS 
amylamine was an even more effective inhibitor of tumor angio- Statin), as did mecamylamine (p  .0005). Statins did not have a significant
genesis, nearly abrogating the entire increase in capillary density effect in the absence of SHS (p  .468 for size and p  .339 for weight).
Error bars indicate standard deviations.induced by SHS (p  .0005).
SHS and mediators of tumor angiogenesis
Plasma VEGF and MCP-1 levels were determined by immunoas-
Discussionsay. SHS increased plasma VEGF levels more than 2-fold (Figure
2B). Cerivastatin had no effect in mice breathing clean room
The salient findings of this study are: (1) second hand smoke
air, but tended to reduce VEGF levels (by 25%) in mice exposed
(SHS) significantly increases tumor size, weight, and vascularity;
to SHS (p  .145). Mecamylamine blocked about two-thirds of (2) SHS increases serum VEGF and MCP-1 levels; (3) SHS in-
the increase in VEGF induced by SHS (p  .0005). creases the number of circulating endothelial progenitor cells;
SHS doubled serum MCP-1 levels (p  .0005) (Figure 2C). and (4) Antagonism of the nACh receptor, or inhibition of
Although cerivastatin had no effect in mice breathing clean room isoprenoid metabolism, reverses in part these effects of SHS.
air, it blocked three-quarters of the increase in MCP-1 levels Specifically, the nicotine acetylcholine receptor antagonist,
induced by SHS (p  .0005). Mecamylamine had a smaller, mecamylamine, reduced the effects of SHS on tumor size,
marginally significant (p  .050) effect on MCP-1 levels. weight, and vascularity, as well as levels of circulating MCP-1,
Circulating endothelial progenitor cells were detected by VEGF, and endothelial progenitor cells. The HMG-CoA reduc-
flow cytometry and were defined by positive staining for CD34 tase inhibitor, cerivastatin, reduced the effects of SHS on tumor
and flk-1. The number of circulating endothelial progenitor cells size, weight, and vascularity and reduced serum MCP-1 levels.
tripled in the SHS mice (p  .0005; Figure 2D). Cerivastatin had Statins did not significantly modulate the effects of SHS on
no significant effect on circulating endothelial progenitor cells. VEGF or circulating endothelial progenitor cells. Statins, at the
Mecamylamine blocked about one-third of the increase in circu- dose we used, did not affect any of the variables we measured
lating endothelial progenitor cells associated with SHS (p  in mice breathing clean room air.
SHS, the tobacco combustion products inhaled by non-.0005).
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Figure 2. SHS promotes tumor angiogenesis
A: SHS increased capillary density in the tumors (p  .0005). Cerivastatin (p  .018 for SHS  statin) and mecamylamine (p  .0005) partially blocked this
effect.
B: Plasma VEGF levels increased in mice exposed to SHS (p  .0005). Cerivastatin tended to inhibit this effect (p  .145 for SHS  statin). Mecamylamine
blocked about two-thirds of the effect of SHS (p  .0005).
C: MCP-1 levels increased in mice exposed to SHS (p  .0005). Cerivastatin blocked most of this effect (p  .0005 for SHS  Statin); mecamylamine had a
smaller effect (p  .050).
D: The number of circulating endothelial progenitor cells (EPS) increased with SHS (p  .0005). Cerivastatin did not significantly blunt this effect (p  .271
for SHS  Statin); mecamylamine blocked about one-third of the effect of SHS (p  .0005). Cerivastatin in the absence of SHS did not have a statistically
significant effect on any variable (p  .733 for capillary density, p  .637 for VEGF, p  .829 for MCP-1, p  .768 for ECP). Error bars indicate standard
deviations.
smokers in the proximity of burning tobacco, is dangerous be- at these levels increases experimental atherosclerosis in rabbits
and myocardial infarct size in rats (Zhu et al., 1993, 1994).cause it contains high concentrations of nicotine, benzene, poly-
We have observed anatomic and functional evidence thatcyclic aromatic hydrocarbons, fine particles (PM2.5), and many
nicotine induces angiogenesis and accelerates the growth ofother carcinogens and irritants (US Environmental Protection
tumor and atheroma in association with increased lesion vascu-Agency, 1992; Glantz and Parmley, 1992; Cooke and Bitterman,
larity, these effects mediated by nicotinic acetylcholine recep-2003). The exposure chamber we used had an interior volume
tors (Heeschen et al., 2001, 2002, 2003). Signaling pathways(3.6 m3) similar to that of an automobile sedan (3.7 m3). If four
mediating the effect of nicotine on endothelial network formation
passengers each smoked four cigarettes per hour, that microen- include phosphatidylinositol-3-kinase and mitogen-activated
vironment would be similar to the one in the present study. The protein kinase pathways that converge on the activation of NF-
plasma cotinine concentrations we observed in our mice (150- B (Heeschen et al., 2002). Our current results are consistent
200 ng/ml) are comparable to what would be expected from a with the hypothesis that nicotine activates an endogenous angi-
heavy level of passive smoking, as in a casino, bingo parlor, or ogenic pathway mediated by endothelial nACh receptors. Fur-
thermore, our observations indicate that nicotine absorbed frombar room. Our previous studies indicated that exposure to SHS
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SHS can exert a substantial effect on tumor angiogenesis and tumors are less immunogenic than experimental tumors (Hewitt
et al., 1976).growth at levels of exposure experienced by people in smoky
In conclusion, exposure to SHS at levels observed in smokyenvironments.
environments stimulates tumor growth, tumor angiogenesis,The effects of nicotine may be mediated in part by activation
and an increase in growth factors and cells known to contributeof endothelial-monocyte interactions involved in arteriogenesis.
to tumor angiogenesis (Figure 3). These effects were reducedNicotine has been shown to activate human monocyte-derived
by mecamylamine, a nicotinic receptor antagonist, and cerivas-dendritic cells and to augment their capacity to stimulate T cell
tatin, an inhibitor of isoprenoid synthesis. This study indicatesproliferation and cytokine secretion (Aicher et al., 2003). Further-
that the oncogenic effects of SHS are mediated in part by angio-more, nicotine increases serum VEGF levels (Heeschen et al.,
genic effects of nicotine.2001). These data are consistent with our observation that mec-
amylamine (an antagonist of nACh receptors) blocks the effect
Experimental proceduresof SHS to increase serum VEGF and MCP-1 levels.
Mecamylamine (but not cerivastatin) blocked the effect of Lewis lung cancer model
SHS to increase the number of circulating endothelial precursor Lewis lung carcinoma cells (ATCC, Manassas, Virginia) were cultured in
cells. This may related to the effect of mecamylamine to block RPMI 1640 supplemented with 10% FBS. Lewis lung carcinoma cells (1 
106 cells/mouse) were subcutaneously injected unilaterally into the right flankSHS-induced increases in serum VEGF levels, as administration
of C57BL/6J wild-type mice (8 weeks, 20–24 g).of exogenous VEGF is known to stimulate the release of endo-
thelial progenitors into the circulation (Rabbany et al., 2003).
Experimental groups
Alternatively, mecamylamine may block a direct effect of nico- Forty three mice were randomized into five groups (n  8 or 9 each group)
tine on mobilization of endothelial progenitors. after implantation of Lewis lung cancer cells: (1) clean room air-no drugs;
HMG-CoA reductase inhibitors (i.e., statins) such as cerivas- (2) clean room air-statin (cerivastatin; Bayer, Germany); (3) SHS-no drugs; (4)
SHS-statin; and (5) SHS-mecamylamine (a nicotinic acetylcholine receptortatin and atorvastatin have a biphasic dose-dependent effect
antagonist; Sigma, St. Louis, Missouri). The mice in the three SHS groupson angiogenesis that is independent of their effect on plasma
were exposed to sidestream tobacco smoke in an exposure chamber (modelcholesterol (Weis et al., 2002). At low doses, statins have a
H 5500, BioClean, Duo Flo, Lab Product Inc.) that had a 3.6 m3 interior
proangiogenic effect mediated by increases in NO synthase volume, similar to that of an automobile sedan. Four Marlboro filter cigarettes
expression and activity (Weis et al., 2002). At high doses, statins were smoked using a smoking machine (RM 1/G, Heiner Borgwald GmbH,
strongly inhibit endothelial cell locomotion and capillary tube Hamburg, Germany) every 15 min, 6 hr/day, five days/week in the exposure
chamber. The mice in the two non-SHS groups were exposed to clean roomformation (Vincent et al., 2001; Weis et al., 2002), actions which
air. The mecamylamine (0.24 mg/kg per day) and cerivastatin (2.5 mg/kg permay explain the antiangiogenic effects we observed. Further-
day) were administered by osmotic minipumps (Durect, Cupertino, California)more, we find that cerivastatin blunts the increase in MCP-1
subcutaneously implanted in the left lower dorsal area of the mice. After 17
levels associated with SHS. This is consistent with the reports days, all mice were sacrificed due to substantial tumor growth in animals
cited above (Vincent et al., 2001; Weis et al., 2002) and suggests of the vehicle-treated SHS group. The cotinine levels in the three SHS groups
that the anti-inflammatory effects of statins contribute to were similar and significantly higher than the two clean room air groups.
There was no interaction of the drugs with cotinine levels.blocking the angiogenic effects of SHS. By inhibiting HMG-CoA
reductase, statins block the formation of isoprenoid products of
Laboratory measurementsmevalonate. Isoprenoids such as geranylgeranyl pyrophosphate
Tumor size was determined with a digital caliper (4/3   length/2  width/provide lipophilic anchors that are essential for membrane at-
2  thickness/2). Plasma cotinine levels, a measure of exposure to nicotine,
tachment and biological activity of small GTP binding proteins were measured by STC Technologies (Bethlehem, Pennsylvania). Plasma
such as Rho A and Ras (Yoshida et al., 1991; Elson et al., 1999). VEGF levels were determined with a mouse VEGF ELISA kit (R&D Systems,
Minneapolis, Minnesota). The MCP-1 levels were determined using a mouseRho A is a small GTP binding protein crucial for the organization
JE/MCP-1 immunoassay (R&D Systems). Circulating endothelial progenitorof the actin cytoskeleton and therefore for cell locomotion re-
cells were determined by flow cytometry and were defined by positive stain-quired for angiogenesis (Menager et al., 1999). Geranylgeranyla-
ing for CD34 (BD Pharmingen, San Diego, California) and flk-1 (BD Phar-tion of Rho is required for its membrane localization and translo-
mingen). Data were analyzed using CellQuest software (Becton Dickinson),
cation and participation in angiogenic signaling (Park et al., and all staining was referred to isotype-matched control antibodies pur-
2002). Ras is involved in regulation of the mitogen-activated chased from BD Pharmingen. Tumor vascularity was determined in 10 m
cryosections of tumor tissue derived from mice that had received a systemicprotein kinase and nuclear factor-kappa B pathways involved
infusion of space-filling fluorescent microspheres (0.2m; Molecular Probes)in angiogenesis (Finco et al., 1997; Berra et al., 2000; Shono et
via the left ventricle (Heeschen et al., 2001).al., 1996). The antiangiogenic effects of the statins may explain
the unanticipated observation that cancer deaths are reduced
Statistical analysis
in some large trials of statins for prevention of cardiovascular Values are presented as mean  standard deviation. Statistical hypothesis
events (Pedersen et al., 2000). However, with respect to the testing was done with a general linear model:
mechanisms by which SHS contributes to human malignancy,
y  bControl  bSHS SHS  bStatin Statin  bSHSxStatin SHSxStatin  bMeca Mecafurther work needs to be done to confirm the relevance of our
observations. We used a murine cell line (Lewis lung cancer where y is the variable of interest and SHS  1 if the mouse was exposed
to secondhand smoke, Statin  1 if the mouse received cerivastatin, andcells) to study tumor angiogenesis and growth in vivo. The cellu-
Meca  1 if the mouse received mecamylamine; otherwise these variableslar processes and factors mediating angiogenesis in naturally
were set to 0. bControl is the estimate of the dependent variable for animalsoccurring human tumors may be different than those induced
breathing clean room air with no drugs, bSHS is the change in y associatedby tumor cell lines. For example, there is less evidence for an with SHS independent of the presence of cerivastatin or mecamylamine,
inflammatory response in human tumors than in those induced bStatin is the change associated with the statin, independent of the presence
of SHS, bSHSxStatin is the SHS by Statin interaction (a measure of differentialby transplanted cell lines in animals, indicating that spontaneous
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Figure 3. Mechanisms by which SHS promotes malignancy
SHS contains over 4000 compounds, some of which are mutagenic. In addition, nicotine in SHS stimulates nicotinic cholinergic receptors (nAChRs) on
endothelial cells and monocytes to trigger calcium entry and signaling events. The post-receptor signaling is in part mediated by small GTPase proteins
that require isoprenylation for their activity. The activity of these proteins (e.g., Ras and Rho) is inhibited by HMG-CoA reductase inhibitors, i.e., statins) that
block their isoprenylation. Endothelial cells stimulated by nicotine release factors such as fibroblast growth factor (FGF), vascular endothelial growth factor
(VEGF), and nitric oxide (NO), which mediate angiogenesis. These agents, together with nicotine, enhance endothelial cell (EC) survival, proliferation, and
migration and also recruit endothelial progenitor cells (EPCs). Stimulation of nAChRs on dendritic cells induces their activation of T lymphocytes and release
of inflammatory mediators that contribute to EC activation. These processes favor angiogenesis, which promotes the vascularization and growth of
malignant cells.
effects of the statin in the presence or absence of SHS), and bMeca is the Revised: August 4, 2003
change associated with mecamylamine (in the presence of SHS since meca- Published: September 22, 2003
mylamine was only given to mice who were exposed to SHS). Raw observa-
tions are presented as mean  standard deviation. p values are associated References
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